Achiko AG appointed biotechnology research scientist and entrepreneur Dr. Morris S. Berrie to the position of President, and business leader in the life science industry Richard Lingard to the position of SVP Commercialisation. Dr. Berrie brings over 20 years of scientific, business and financial experience in the biotechnology and healthcare industries. He served as Co-Founder/Chairman of TTS Global Initiative which globally facilitates deal flow in the early stage/SME biotech sector and was a partner of several EU Horizon 2020 multimillion Euro projects aiding the European SME sector. He is also Director of Tech Investor Ltd. which consults and advises government organisations, regions and companies throughout the biotech sector on the commercialisation of science, including business development and capital raising. Prior, Dr. Berrie was the Chief Executive Officer and Editor-in-Chief of the Biotechnology Investment Today Group where he worked with numerous prestigious clients from both the healthcare and the financial industries, including the US National Institutes of Health (NIH), Pfizer, GSK, Needham & Co, Orbimed, TVM, JPMorgan and many more.Mr. Lingard is an accomplished business leader with over 25 years' experience in the life science industry. He has a chemistry background and has worked with a range of multinational corporations, contract research organizations (CROs) and start-up companies. Previously, he was CEO of Adroit-DI, where he developed a software platform to unify research. Mr. Lingard was Head of Europe, Middle East, India and Russia for Taconic Biosciences, creating a partner ecosystem and structuring his division to assist with the sale of Taconic to H.I.G. Capital.